ATE70717T1 - Vermehrung der antigenimmunogenizitaet. - Google Patents

Vermehrung der antigenimmunogenizitaet.

Info

Publication number
ATE70717T1
ATE70717T1 AT87304005T AT87304005T ATE70717T1 AT E70717 T1 ATE70717 T1 AT E70717T1 AT 87304005 T AT87304005 T AT 87304005T AT 87304005 T AT87304005 T AT 87304005T AT E70717 T1 ATE70717 T1 AT E70717T1
Authority
AT
Austria
Prior art keywords
antigen
cells
monoclonal antibody
targeting
specific
Prior art date
Application number
AT87304005T
Other languages
English (en)
Inventor
Brian Harold Barber
George Carayannotis
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Application granted granted Critical
Publication of ATE70717T1 publication Critical patent/ATE70717T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87304005T 1986-05-06 1987-05-05 Vermehrung der antigenimmunogenizitaet. ATE70717T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868610983A GB8610983D0 (en) 1986-05-06 1986-05-06 Enhancement of antigen immunogenicity
EP87304005A EP0245078B1 (de) 1986-05-06 1987-05-05 Vermehrung der Antigenimmunogenizität

Publications (1)

Publication Number Publication Date
ATE70717T1 true ATE70717T1 (de) 1992-01-15

Family

ID=10597389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87304005T ATE70717T1 (de) 1986-05-06 1987-05-05 Vermehrung der antigenimmunogenizitaet.

Country Status (6)

Country Link
US (1) US4950480A (de)
EP (1) EP0245078B1 (de)
JP (1) JPH0674210B2 (de)
AT (1) ATE70717T1 (de)
DE (1) DE3775458D1 (de)
GB (1) GB8610983D0 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US5173293A (en) * 1989-02-23 1992-12-22 Becton Dickinson And Company Anti-T-cell antibodies as adjuvants
GB8907310D0 (en) * 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
CA2015515C (en) 1990-01-03 1999-12-07 Jean-Marie Saint-Remy Pharmaceutical compositions containing antigen-antibody complexes and uses therefor
JP3583420B2 (ja) * 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
US6248332B1 (en) 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
US5107060A (en) * 1990-10-17 1992-04-21 Mobil Oil Corporation Thermal cracking of mercury-containing hydrocarbon
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5686078A (en) * 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
ATE395422T1 (de) 1995-06-07 2008-05-15 Sanofi Pasteur Ltd Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
US6328962B2 (en) * 1995-06-07 2001-12-11 Aventis Pasteur Limited Method for delivery of antigens to selected cells of the immune system using chimeric antibodies
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
AU703120B2 (en) * 1995-10-20 1999-03-18 University Of Nebraska Board Of Regents Composition and methods for enhancing immune responses mediated by antigen-presenting cells
CA2240834C (en) * 1995-12-22 2013-12-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
EP0871747A1 (de) * 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
SI0910407T1 (en) * 1996-05-15 2003-10-31 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
FR2759296B1 (fr) * 1997-02-07 1999-04-09 Commissariat Energie Atomique Complexe non-covalent comprenant au moins un anticorps et un element de liaison aux immunoglobulines associe a une substance active, son procede de preparation et ses applications
US20020025315A1 (en) * 1998-01-14 2002-02-28 Naveen N. Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US20050031619A1 (en) * 2001-03-21 2005-02-10 Nicodemus Christopher F. Therapeutic compositions that alter the immune response
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
AU2002363861A1 (en) * 2001-11-30 2003-06-10 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an intigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
AU2002231655A1 (en) * 2001-11-30 2003-06-10 Crucell Holland B.V. Antigen presenting cell targeting conjugate an antigen presenting cell contacted with such conjugate their use for vaccination or as medicament and methods for their production or generation
WO2003086041A2 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
AU2004209644A1 (en) * 2003-02-03 2004-08-19 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
EP1685236A4 (de) * 2003-09-29 2008-01-23 Univ California Verfahren zur änderung der adhäsion, differenzierung und migration hämatopoetischer vorläuferzellen
CA2685308A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
ES2703780T3 (es) 2011-05-17 2019-03-12 Trion Res Gmbh Preparación de una vacuna que contiene anticuerpos trifuncionales con propiedades potenciadoras de la inmunogenicidad del antígeno

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031812B1 (de) * 1979-03-27 1983-06-15 National Research Development Corporation Verbesserungen an immunologischen zusammensetzungen
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
EP0142905A2 (de) * 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutisches Mittel für die Behandlung von Krankheiten wie Krebs
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
JPS6072826A (ja) * 1983-09-26 1985-04-24 バイオ−レスポンス・インコ−ポレ−テツド 疾患細胞の生体内治療物質

Also Published As

Publication number Publication date
EP0245078A3 (en) 1989-07-12
GB8610983D0 (en) 1986-06-11
US4950480A (en) 1990-08-21
EP0245078B1 (de) 1991-12-27
JPH0674210B2 (ja) 1994-09-21
EP0245078A2 (de) 1987-11-11
JPS6345228A (ja) 1988-02-26
DE3775458D1 (de) 1992-02-06

Similar Documents

Publication Publication Date Title
DE3775458D1 (de) Vermehrung der antigenimmunogenizitaet.
ATE463255T1 (de) Künstliche t-helferzell-epitope als immunstimulatoren für synthetische peptidimmunogene
DE3588022D1 (de) Pre-S-Gen kodierte Hepatitis-B immunogene Peptide, Vakzine, Diagnostika und synthetische lipidische Bläschenträger.
Webster The immune response to influenza virus: III. Changes in the avidity and specificity of early IgM and IgG antibodies
ATE317267T1 (de) Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
DK174416B1 (da) Oligopeptider, immunogene konjugater heraf med et antigen samt vacciner indeholdende disse konjugater
IL102687A (en) Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
Thraenhart et al. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man
NZ219113A (en) Hiv peptide containing epitope of the env protein
Jemmerson et al. Mapping antigenic sites on proteins: Implications for the design of synthetic vaccines.
ATE47524T1 (de) Hundeparvovirus-impfstoffe.
ATE302016T1 (de) Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind
WO1999013907A3 (en) Methods to improve immunogenicity of antigens and specificity of antibodies
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
O'meara et al. Recombinant vaccines against ovine footrot
Lopez-Macias et al. Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization
EP0303309A3 (en) A genus-specific listeria antigen identified by monoclonal antibodies
Bouwer et al. Cytotoxic-T-lymphocyte responses to epitopes of listeriolysin O and p60 following infection with Listeria monocytogenes
Tabatabai et al. Characterization of salt-extractable protein antigens from Brucella abortus by crossed immunoelectrophoresis and isoelectricfocusing
Petersen et al. Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine
ATE284897T1 (de) Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen
Hachimura et al. Relative positioning of the T cell and B cell determinants on an immunogenic peptide: its influence on antibody response
GB2314560A (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparations and use
FI894048A0 (fi) Menetelmä Pseudomonas aeruginosa-infektioita vastaan vaikuttavien valmisteiden sekä immunoglobuliini-G-pitoisten, Pseudomonas aeruginosa-bakteeria vastaan vaikuttavien valmisteiden tuottamiseksi
IT1189295B (it) Composizione antigenica sintetica e procedimento per la sua preparazione

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time